The National Commission on Correctional Health Care (NCCHC) has awarded the contract to publish Journal of Correctional Health Care to Mary Ann Liebert, Inc., publishers, effective January 2021.
A sizable research consortium coordinated by NTNU and St. Olavs Hospital will analyse large amounts of MRI exam data from around the world. The data will help researchers gain important new understanding about brain injuries in people who have had trauma to the head. The goal is to improve patient health care.
A new finding about dexamethasone suggests diabetes and other factors may reduce its potentially lifesaving effectiveness for patients with severe COVID-19.
University of Minnesota Medical School researchers found that taking hydroxychloroquine once or twice weekly did not prevent the development of COVID-19 in health care workers better than the placebo.
According to an open-access article in ARRS' American Journal of Roentgenology (AJR), the use of spectral CT with electron density imaging could improve the assessment of lung lesion extent in patients with early-stage coronavirus disease (COVID-19).
New research suggests an algorithm could be used to help optimise the sharing of healthcare resources during the Covid-19 pandemic, preventing NHS intensive care units (ICU) from becoming overwhelmed.
In patients initiating continuous renal replacement therapy for acute kidney injury, higher serum creatinine-to-cystatin C ratios were associated with lower mortality.
NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%). They can become a safe alternative to the usual antibiotics in implantology since they do not have typical negative side effects. The results of the work are published in the international scientific journal ACS Applied Materials & Interfaces.
The investigators found that when tocilizumab was administered within the first two days of intensive care unit (ICU) admission, there was a 30 percent relative decrease (and a 10 percent absolute decrease) in mortality compared to patients whose treatment did not include early use of tocilizumab.
Whether treatment with tocilizumab in the first two days after being admitted to an intensive care unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated in this study.